Improving outcome reporting in clinical trial reports and protocols: study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT).
CONSORT
Endpoint
Outcome
Reporting guideline
SPIRIT
Trial
Trial protocol
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
06 Mar 2019
06 Mar 2019
Historique:
received:
17
09
2018
accepted:
12
02
2019
entrez:
8
3
2019
pubmed:
8
3
2019
medline:
18
7
2019
Statut:
epublish
Résumé
Inadequate and poor quality outcome reporting in clinical trials is a well-documented problem that impedes the ability of researchers to evaluate, replicate, synthesize, and build upon study findings and impacts evidence-based decision-making by patients, clinicians, and policy-makers. To facilitate harmonized and transparent reporting of outcomes in trial protocols and published reports, the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT) is being developed. The final product will provide unique InsPECT extensions to the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) and CONSORT (Consolidated Standards of Reporting Trials) reporting guidelines. The InsPECT SPIRIT and CONSORT extensions will be developed in accordance with the methodological framework created by the EQUATOR (Enhancing the Quality and Transparency of Health Research Quality) Network for reporting guideline development. Development will consist of (1) the creation of an initial list of candidate outcome reporting items synthesized from expert consultations and a scoping review of existing guidance for reporting outcomes in trial protocols and reports; (2) a three-round international Delphi study to identify additional candidate items and assess candidate item importance on a 9-point Likert scale, completed by stakeholders such as trial report and protocol authors, systematic review authors, biostatisticians and epidemiologists, reporting guideline developers, clinicians, journal editors, and research ethics board representatives; and (3) an in-person expert consensus meeting to finalize the set of essential outcome reporting items for trial protocols and reports, respectively. The consensus meeting discussions will be independently facilitated and informed by the empirical evidence identified in the primary literature and through the opinions (aggregate rankings and comments) collected via the Delphi study. An integrated knowledge translation approach will be used throughout InsPECT development to facilitate implementation and dissemination, in addition to standard post-development activities. InsPECT will provide evidence-informed and consensus-based standards focused on outcome reporting in clinical trials that can be applied across diverse disease areas, study populations, and outcomes. InsPECT will support the standardization of trial outcome reporting, which will maximize trial usability, reduce bias, foster trial replication, improve trial design and execution, and ultimately reduce research waste and help improve patient outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Inadequate and poor quality outcome reporting in clinical trials is a well-documented problem that impedes the ability of researchers to evaluate, replicate, synthesize, and build upon study findings and impacts evidence-based decision-making by patients, clinicians, and policy-makers. To facilitate harmonized and transparent reporting of outcomes in trial protocols and published reports, the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT) is being developed. The final product will provide unique InsPECT extensions to the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) and CONSORT (Consolidated Standards of Reporting Trials) reporting guidelines.
METHODS
METHODS
The InsPECT SPIRIT and CONSORT extensions will be developed in accordance with the methodological framework created by the EQUATOR (Enhancing the Quality and Transparency of Health Research Quality) Network for reporting guideline development. Development will consist of (1) the creation of an initial list of candidate outcome reporting items synthesized from expert consultations and a scoping review of existing guidance for reporting outcomes in trial protocols and reports; (2) a three-round international Delphi study to identify additional candidate items and assess candidate item importance on a 9-point Likert scale, completed by stakeholders such as trial report and protocol authors, systematic review authors, biostatisticians and epidemiologists, reporting guideline developers, clinicians, journal editors, and research ethics board representatives; and (3) an in-person expert consensus meeting to finalize the set of essential outcome reporting items for trial protocols and reports, respectively. The consensus meeting discussions will be independently facilitated and informed by the empirical evidence identified in the primary literature and through the opinions (aggregate rankings and comments) collected via the Delphi study. An integrated knowledge translation approach will be used throughout InsPECT development to facilitate implementation and dissemination, in addition to standard post-development activities.
DISCUSSION
CONCLUSIONS
InsPECT will provide evidence-informed and consensus-based standards focused on outcome reporting in clinical trials that can be applied across diverse disease areas, study populations, and outcomes. InsPECT will support the standardization of trial outcome reporting, which will maximize trial usability, reduce bias, foster trial replication, improve trial design and execution, and ultimately reduce research waste and help improve patient outcomes.
Identifiants
pubmed: 30841935
doi: 10.1186/s13063-019-3248-0
pii: 10.1186/s13063-019-3248-0
pmc: PMC6404348
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
161Subventions
Organisme : Canadian Institutes of Health Research
ID : #148953
Pays : Canada
Références
J Adv Nurs. 2000 Oct;32(4):1008-15
pubmed: 11095242
JAMA. 2004 May 26;291(20):2457-65
pubmed: 15161896
Ann Intern Med. 2004 Nov 16;141(10):781-8
pubmed: 15545678
BMJ. 2005 Apr 2;330(7494):753
pubmed: 15681569
Lancet. 2005 Mar 26-Apr 1;365(9465):1159-62
pubmed: 15794971
Med J Aust. 2006 Sep 4;185(5):263-7
pubmed: 16948622
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Lancet. 2009 Jul 4;374(9683):86-9
pubmed: 19525005
PLoS Med. 2010 Feb 16;7(2):e1000217
pubmed: 20169112
BMJ. 2010 Mar 23;340:c723
pubmed: 20332510
BMJ. 2010 Mar 23;340:c869
pubmed: 20332511
Pediatrics. 2010 Jul;126(1):e222-31
pubmed: 20566617
J Invest Dermatol. 2011 Mar;131(3):623-30
pubmed: 20944653
PLoS Med. 2011 Jan 25;8(1):e1000393
pubmed: 21283604
Pediatrics. 2012 Jun;129 Suppl 3:S146-52
pubmed: 22661761
J Womens Health (Larchmt). 2012 Sep;21(9):925-32
pubmed: 22747422
Trials. 2012 Aug 06;13:132
pubmed: 22867278
Cochrane Database Syst Rev. 2012 Nov 14;11:MR000030
pubmed: 23152285
Health Policy. 2013 Feb;109(2):187-91
pubmed: 23228520
Br J Gen Pract. 2012 Oct;62(603):e729-31
pubmed: 23265234
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
JAMA. 2013 Feb 27;309(8):814-22
pubmed: 23443445
PLoS One. 2013 Jul 05;8(7):e66844
pubmed: 23861749
J Clin Epidemiol. 2013 Dec;66(12):1367-75
pubmed: 24075598
Adm Policy Ment Health. 2015 Sep;42(5):533-44
pubmed: 24193818
Lancet. 2014 Jan 18;383(9913):267-76
pubmed: 24411647
Lancet. 2014 Jan 18;383(9913):257-66
pubmed: 24411650
J Clin Epidemiol. 2014 Apr;67(4):401-9
pubmed: 24581294
Trials. 2014 Jun 25;15:247
pubmed: 24962012
PLoS One. 2014 Oct 16;9(10):e109400
pubmed: 25329377
PLoS One. 2014 Oct 15;9(10):e110216
pubmed: 25333995
J Am Acad Child Adolesc Psychiatry. 2015 Feb;54(2):138-46
pubmed: 25617254
Trials. 2015 Jun 17;16:275
pubmed: 26081254
PLoS One. 2015 Jun 26;10(6):e0129514
pubmed: 26115172
Implement Sci. 2016 Mar 17;11:38
pubmed: 26988000
J Clin Epidemiol. 2017 Jan;81:33-41
pubmed: 27667370
PLoS Med. 2016 Oct 18;13(10):e1002148
pubmed: 27755541
Trials. 2017 Mar 14;18(1):122
pubmed: 28288676
J Clin Epidemiol. 2017 Jun;86:39-50
pubmed: 28529187
Ann Transl Med. 2017 May;5(Suppl 1):S15
pubmed: 28567397
BMJ. 2017 Jun 8;357:j2490
pubmed: 28596181
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
JAMA. 2017 Nov 7;318(17):1709-1711
pubmed: 28892118
JAMA. 2017 Dec 19;318(23):2337-2343
pubmed: 29260229
JAMA. 2018 Feb 6;319(5):483-494
pubmed: 29411037
BMJ Paediatr Open. 2017 May 18;1(1):null
pubmed: 29637088
BMJ Open. 2019 Feb 19;9(2):e023001
pubmed: 30782872
J Rheumatol. 1993 Mar;20(3):528-30
pubmed: 8478864